Danaher's Valuation Discount to Thermo Fisher Sparks Pairs Trade Analysis

A significant valuation spread has emerged between Danaher (DHR) and Thermo Fisher Scientific (TMO), two dominant players in the Life Sciences Tools & Services sector. An analysis by Investing.com highlights that while both companies operate with similar business moats, their market valuations have diverged, prompting consideration of a market-neutral pairs trade.

The Valuation Divide

According to the analysis, Danaher currently appears more attractively valued than Thermo Fisher across several key metrics. While both stocks are considered richly valued, the degree of overvaluation differs. The data, as of September 21, suggests Thermo Fisher is trading 15.1% above its fair value, while Danaher is only 7.1% above its fair value.

Key valuation points favoring Danaher include:

• Forward P/E Ratio: DHR at 24.7x versus TMO at 25.8x.
• EV/EBITDA: DHR at 21.6x versus TMO at 24.0x.
• Free Cash Flow Yield: DHR at 3.6% compared to TMO's 3.0%.
• Balance Sheet: Danaher carries a lower debt-to-equity ratio of 53.0%, compared to 80.8% for Thermo Fisher.

Notably, Danaher's gross margin of 59.2% significantly outpaces Thermo Fisher's 41.1%, which the analysis attributes to a higher-quality business mix in its bioprocessing and diagnostics segments.

Justifying Thermo Fisher's Premium

Ad

Thermo Fisher's higher valuation is not without justification. The company demonstrates superior capital allocation and growth metrics, which typically command a premium from investors. TMO's Return on Equity (ROE) of 13.5% nearly doubles Danaher's 7.6%, and its Return on Invested Capital (ROIC) is also stronger at 8.3% versus DHR's 6.2%.

Furthermore, Thermo Fisher has posted stronger last-twelve-months (LTM) revenue growth of 7.2% compared to Danaher's 4.6%. The bear case for Danaher centers on a significant earnings-per-share compression since 2022, as the tailwinds from the COVID-19 pandemic's impact on bioprocessing have reversed.

The Pairs Trade Thesis

The core of the analysis proposes a market-neutral strategy: a long position in Danaher (DHR) paired with a short position in Thermo Fisher (TMO). This trade is designed to profit from the potential narrowing of the valuation gap between the two stocks, irrespective of the overall direction of the life sciences sector.

Technical indicators also play a role in the thesis. Thermo Fisher's weekly Relative Strength Index (RSI) of 71.3 is in "overbought" territory, signaling its strong trend may be extended and susceptible to a pullback. In contrast, Danaher's weekly RSI is a more moderate 57.2, suggesting less exhaustion risk. Potential catalysts that could close the spread include a DHR earnings beat, a TMO guidance miss, or a broader market rotation toward stocks perceived as having better relative value.